Alkermes plc ALKS
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +60.44%
- 1 year
- +46.22%
- Open
- 45.59
- Prev close
- 45.34
- Mkt cap
- 7.53B
- Vol
- 2.16M
- Avg vol
- 1.83M
- EPS
- 0.38
- P/E
- 118.13
- Div yield
- 0.00%
More statistics
- Low
- 44.49
- High
- 45.92
- Forward P/E
- 24.80
- Beta
- 0.23
- Short ratio
- 7.67
- Inst. own
- 107.88%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 44.06
- 200-d avg
- 40.48
- 1y target
- 56.21
News
21 hours ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares…
3 days ago businesswire.com
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in…
4 days ago seekingalpha.com
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story
Alkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ's commercial momentum and a promising neuroscience pipeline. 3Q26 revenue is projected to rise 18% year-over-year but…
-
2 weeks ago benzinga.com
Alkermes Plans To Present Two Oral Presentations And Six Posters From Portfolio Of Sleep Medicine Research At ESRS 28th Congress, Sleep Europe 2026
— Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be…